Registry for Migraine - Clinical Core (REFORM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Messoud Ashina, MD
- Phone Number: +4538633385
- Email: ashina@dadlnet.dk
Study Contact Backup
- Name: Faisal Amin, MD
- Phone Number: +4538633186
- Email: amin.faisal@hotmail.com
Study Locations
-
-
-
Glostrup, Denmark, 2600
- Recruiting
- Danish Headache Center
-
Contact:
- Messoud Ashina, MD
- Phone Number: +45 38 63 33 85
- Email: ashina@dadlnet.dk
-
Contact:
- Faisal Amin, MD
- Phone Number: +4538633186
- Email: amin.faisal@hotmail.com
-
Principal Investigator:
- Messoud Ashina, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has provided informed consent prior to initiation of any study-specific activities/procedures
- Age greater than or equal to 18 years upon entry into screening
- History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self report
- Greater than or equal to 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening after baseline period
- Must have demonstrated greater than or equal to 75% compliance in headache diiary usage during baseline period
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria apply:
Disease Related
- Greater than 50 years of age at migraine onset
- History of cluster headache or hemiplegic migraine headache
- Inability to differentiate between migraine from other headaches
- The subject is at risk of self-harm or harm to others as evidenced by past suicidal behaviour
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion Prior/Concomitant Therapy
- Previously received erenumab (Aimovig®)
- Received an anti-CGRP monoclonal antibody within 3 months prior to the start of the baseline period Prior/Concurrent Clinical Study Experience
- Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study (ies). Other investigational procedures while participating in this study are excluded.
Other Exclusions
- Female subjects of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test.
- Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product.
- Female subjects of childbearing potential unwilling to use 1 acceptable method of effective contraception during treatment and for an additional 16 weeks after the last dose of investigational product.
- Evidence of current pregnancy or breastfeeding per subject self-report or medical records
- Subject has known sensitivity to any of the products or components to be administered during dosing
- Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single-Arm
Erenumab packed in a SureClick® Autoinjector Pen (AI)
|
Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Headache Diary
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
Headache diary with daily entries to record migraine-related data.
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Headache Diary
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
Headache diary with daily entries to record migraine-related data.
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
Semi-Structured Interview
Time Frame: Screening Visit (Day -28)
|
In-person semi-structured interview to record migraine-related data.
|
Screening Visit (Day -28)
|
|
Headache Impact Test (HIT-6)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
6-item questionnaire to assess headache-related disability
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
Headache Impact Test (HIT-6)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
6-item questionnaire to assess headache-related disability
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
Migraine Disability Assessment Test (MIDAS)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
7-item questionnaire to assess migraine-related disability
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
Migraine Disability Assessment Test (MIDAS)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
7-item questionnaire to assess migraine-related disability
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
14-item questionnaire to assess anxiety and depression
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
14-item questionnaire to assess anxiety and depression
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
19-item questionnaire to assess quality of sleep
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
19-item questionnaire to assess quality of sleep
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
12-item Allodynia Symptom Checklist (ASC-12)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
12-item questionnaire to allodynia
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
12-item Allodynia Symptom Checklist (ASC-12)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
12-item questionnaire to allodynia
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
Questionnaire to assess health status and disability
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
Questionnaire to assess health status and disability
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
Neck Disability Index (NDI)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
Questionnaire to assess neck disability
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
Neck Disability Index (NDI)
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
Questionnaire to assess neck disability
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
|
Low Back Pain Disability Questionnaire
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 24
|
Questionnaire to assess low back pain disability
|
Baseline Phase (Day -28 to Day 1) to Week 24
|
|
Low Back Pain Disability Questionnaire
Time Frame: Baseline Phase (Day -28 to Day 1) to Week 48
|
Questionnaire to assess low back pain disability
|
Baseline Phase (Day -28 to Day 1) to Week 48
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Erenumab
Other Study ID Numbers
Other Study ID Numbers
- 20019411
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.